Table 1 Ongoing clinical trials as of April 18th, 2020, of vitamin D in the prevention and treatment of human diseases
Study | Year | Disease | Title | Role | Dose of vitamin D | Status | Country | Trial ID# |
|---|---|---|---|---|---|---|---|---|
1 | 2020–2020 | COVID-19 | Vitamin D on Prevention and Treatment of COVID-19 | Prevention, Treatment | A single 25,000 IU | NEW: Not yet recruiting | Spain | NCT04334005 |
2 | 2020–2021 | COVID-19 | A study of hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 infection | Prevention, treatment | Not available | New: Not yet recruiting | USA | NCT04335084 |
3 | 2020–2021 | COVID-19 | A study of quintuple therapy to treat COVID-19 Infection | Prevention, treatment | Not available | New: Not yet recruiting | USA | NCT04334512 |
4 | 2020–2020 | COVID-19 | Proflaxis using hydroxychloroquine plus vitamins-zinc during COVID-19 pandemia | Prevention, treatment | Not available | New: recruiting | Turkey | NCT04326725 |
5 | 2020–2024 | Respiratory infection | Daily vitamin D for sickle-cell respiratory complications | Prevention | 3333 IU daily and 100,000 IU monthly | New: Not yet recruiting | USA | NCT04170348 |
6 | 2010–2020 | Respiratory infection | LungVITamin D and OmegA-3 Trial | Prevention, treatment | 2000 IU daily | Active | USA | NCT01728571 |
7 | 2018–2020 | Respiratory infection | Maintain respiratory muscle function and reduce pneumonia risk in cancer patients | Prevention | Calcitriol, 0.25 µg/daily | Active | USA | NCT03469271 |
8 | 2018–2023 | Respiratory infection | Vitamin D in the prevention of viral-induced asthma in preschoolers | Prevention | 100,000 IU at baseline, followed by 400 IU daily | Active | Canada | NCT03365687 |
9 | 2019–2020 | Respiratory infection | Effect of vitamin D supplementation on improvement of pneumonic Children | Treatment | A single 100,000 IU | Active | Egypt | NCT04244474 |
10 | 2013–2023 | Autoimmune disease | Efficacy of cholecalciferol (vitamin D3) for delaying the diagnosis of MS after a clinically isolated syndrome | Treatment | One 100,000 IU/14 days | Active | France | NCT01817166 |
11 | 2018–2020 | Autoimmune disease | longitudinal effect of vitamin D3 replacement on cognitive performance and MRI markers in multiple sclerosis patients | Treatment | 50,000 IU weekly | Active | Lebanon | NCT03610139 |
12 | 2011–2022 | Autoimmune disease | Vitamin D and fish oil for autoimmune disease, inflammation and knee pain | Prevention, treatment | 2000 IU daily | Active | USA | NCT01351805 |
13 | 2019–2023 | Neurological disorder | High-dose vitamin D supplements in older adults | Prevention | 4000 IU daily | Active | USA | NCT03613116 |
14 | 2017–2023 | Neurological disorder | High-dose vitamin D induction in optic neuritis | Treatment | 5 days of 50,000 IU daily, followed by 10,000 IU daily | Active | USA | NCT03302585 |
15 | 2016–2020 | Neurological disorder | Vitamin D deficiency and dysautonomia | Prevention | Not available | Active | USA | NCT03032328 |